The influence of imatinib mesylate (ST1571) used alone or in combination with purine nucleoside analogoues on the normal and chronic myelogenous leukaemia progenitor cells in vitro

Leukemia and Lymphoma

Volumn 44, Issue 9, 2003, Pages 1549-1555

  Korycka, Anna ^a   Robak, Tadeusz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

2 CdA; Chronic myeloid leukaemia; Fludarabine; Imatinib mesylate; ST1571

Indexed keywords

CLADRIBINE; CYTOTOXIC AGENT; FLUDARABINE; FLUDARABINE PHOSPHATE; IMATINIB; PURINE NUCLEOSIDE DERIVATIVE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CULTURE; CELL GROWTH; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COLONY FORMING UNIT GM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; STEM CELL;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CELL DIVISION; CLADRIBINE; COLONY-FORMING UNITS ASSAY; DRUG SYNERGISM; ENZYME INHIBITORS; FUSION PROTEINS, BCR-ABL; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; TUMOR STEM CELL ASSAY; TUMOR STEM CELLS; VIDARABINE;

EID: 0038574551     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/1042819031000090200     Document Type: Article

References (36)

1. Melo, J.V. (1996) "The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype", Blood 88, 2375-2384.
2. Deininger, M.W.N., Goldman, J.M., Lydon, N. and Melo, J.V. (1997) "The tyrosine kinase inhibitor CGP571148B selectively inhibits the growth of BCR-ABL-positive cells", Blood 90, 3691-3698.
3. Druker, B.J., Talpaz, M., Resta, D.J., Peng, B., Buchdunger, E., Ford, J.M., Lydon, N.B., Kantarijan, H., Capdeville, R., Ohno-Jones, S. and Sawyers, C.L. (2001) "Efficacy and safty od a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia", N. Engl. J. Med. 344, 1031-1037.
4. Druker, B.J., Sawyers, C.L., Kantarijan, H., Resta, D.J., Reese, S.F., Ford, J.M., Cardeville, R. and Talpaz, M. (2001) "Activity of specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with philadelphia chromosome", N. Engl. J. Med. 344, 1038-1042.
5. Sawyers, C.L., Hochhaus, A., Feldman, E., Goldman, J.M., Miller, C.B., Ottmann, O.G., Schiffer, C.A., Talpaz, M., Guilhot, F., Deininger, M.W.N., Fischer, T., O'Brien, S.G., Stone, R.M., Gambacorti-Passerini, C.B., Russel, N.H., Reiffers, J.J., Shea, T.C., Chapuis, B., Coutre, S., Tura, S., Morra, E., Larson, R.A., Saven, A., Peschel, C., Gratwohl, A., Mandelli, F., Ben-Am, M., Gathmann, I., Capdeville, R., Paquette, R.L. and Druker, B.J. (2002) "Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crises: results of a phase II study", Blood 99, 3530-3539.
6. Kantarjian, H.M., Cortes, J., O'Brien, S., Giles, F.J., Albitar, M., Rios, M.B., Shan, J., Faderl, S., Garcia-Manero, G., Thomas, D.A., Resta, D. and Talpaz, M. (2002) "Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase", Blood 99, 3547-3553.
7. Hallek, M., Schmitt, B., Wilhelm, M., Busch, R., Krober, A., Fostitsch, H.P., Sezer, O., Herold, M., Knauf, W., Wendtner, C.M., Kuse, R., Freund, M., Franke, A., Schriever, F., Nerl, C., Dohner, H., Thiel, E., Hiddemann, W., Brittinger, G. and Emmerich, B. (2001) "Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group", Br. J. Haematol. 114, 342-348.
8. Robak, T., Blonski, J.Z., Kasznicki, M., Blasinska-Morawiec, M., Krykowski, E., Dmoszynska, A., Mrugala-Spiewak, H., Skotnicki, A.B., Nowak, W., Konopka, L., Ceglarek, B., Maj, S., Dwilewicz-Trojaczek, J., Hellmann, A., Urasinski, I., Zdziarska, B., Kotlarek-Haus, S., Potoczek, S. and Grieb, P. (2000) "Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial", Blood 96, 2723-2729.
9. Zinzani, P.L., Magagnoli, M., Bendandi, M., Tani, M., Stefoni, V., Cellini, C., Poggi, S., Piccioli, M., Pileri, S. and Tura, S. (2000) "Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyaden-sine", Haematologica 85, 922-925.
10. Gordon, M.S., Young, M.L., Tallman, M.S., Cripe, L.D., Bennett, J.M., Paietta, E., Longo, W., Gerad, H., Mazza, J. and Rowe, J.M. (2000) "Phase II trial of 2-chlorodeoxyadenosine in patients with relapsed/refractory acute myeloid leukemia: a study of the Eastern Cooperative Oncology Group (ECOG), E5995", Leuk. Res. 24, 871-875.
11. Martinelli, G., Zinzani, P.L. and Farabegoli, P. (1996) "Purine analogues (Fludarabine and 2-chlorodeoxyadenosine) as apoptosis-inducing drugs in CML therapy", Hematologica 81, 286-287.
12. Cortes, J., Kantarijan, H., Talpaz, M., O'Brian, S., Koller, C. and Keating, M. (1997) "Treatment of chronic myelogenous leukemia with nucleoside analogues deoxycoformycin and fludarabine", Leukemia 11, 788-791.
13. Saven, A., Piro, L.D., Lemon, R.H., Figueroa, M.L., Kosty, M., Ellison, D.J. and Beutler, E. (1994) "Complete hematologic remission in chronic phase, Philadelphia chromosome-positive, chronic myelogenous leukemia after 2-chlorodeoxy-adenosine", Cancer 73, 2953-2963.
14. Robak, T. and Korycka, A. (1996) "The comparison of 2-chlorodeoxyadenosine (2-CdA) in combination with interferon α (IFNα) or interferon γ (IFNγ) on granulocyte-macrophage progenitor cells (CFU-GM) and clonogenic blasts (CFU-L) in cultures in vitro", Leuk. Lymphoma 21, 161-168.
15. Korycka, A. and Robak, T. (1997) "The influence of recombinant human tumor necrosis factor α and its muteins used alone or in combination with 2-chlorodeoxyadenosine on normal and leukemic hematopoiesis in vitro", Leuk. Res. 21, 857-865.
16. Lech-Maranda, E., Korycka, A. and Robak, T. (2000) "Influence of gemcytabine (2′,2′-difluorodeoxycytidine) and 2-chlorodeoxy-adenosine on growth of normal and leukemic cells in vitro", Eur. J. Haematol. 65, 317-321.
17. Thiesing, J.T., Ohno-Jones, S., Kolibaba, S. and Druker, B.J. (2000) "Efficacy of STI571, an tyrosine kinase inhibitor, in conjunction with other antileukemic agent against Bcr-Abl-positive cells", Blood 96, 3195-3199.
18. Marley, S.B., Davidson, R.J., Lewis, J.L., Nguyen, D.X., Eades, A., Parker, S., Goldman, J.M. and Gordon, M.Y. (2001) "Progenitor cells from patients with advanced phase chronic myeloid leukemia responded to STI571 in vitro and in vivo", Leuk. Res. 25, 997-1002.
19. Kazimierczuk, Z., Vilpo, J., Hildebrand, Z. and Wright, G. (1990) "Synthesis and cytotoxicity of deoxyadenosine analogues: isomer distribution in the sodium salt glycosylation of 2,6-disubstitutes purines", J. Med. Chem. 33, 1683-1687.
20. Iscove, N.N., Sieber, F. and Winterhalter, K.H. (1974) "Erythroid colony formation in culture of mouse and human bone marrow. Analysis of the requirement chromatography on agarose-cancanavalin A", Am. J. Cell Physiol. 83, 309-320.
21. Tosi, P., Visani, G., Ottavina, E., Manfroi, S., Zinzani, P.L. and Tura, S. (1994) "Fludarabine +Ara-C +G-CSF: Cytotoxic effect and induction of apaptosis on fresh acute myeloid leukemia cells", Leukemia 8, 2076-2082.
22. Korycka, A. and Robak, T. (2000) "Amifostine and 2-CdA: a novel purging strategy in CML autografting", Eur. J. Haematol. 64, 347-349.
23. Kristensen, J., Nygren, P., Liliemark, J., Fridborg, H., Killander, A., Simonsson, B., Oberg, G. and Larsson, R. (1994) "Interactions between cladribine (2-chlorodeoxy-adenosine) and standard antileukemic drugs in primary cultures of human tumor cells from patients with acute myelocytic leukemia", Leukemia 8, 1712-1717.
24. Talpaz, M., Silver, R.Y., Druker, B.J., Goldman, J.M., Gambacorti-Passerini, C., Guilhot, F., Schiffer, C.A., Fischer, T., Deininger, M.W.N., Lennard, A.L., Hochhaus, A., Ottmann, O.G., Gratwohl, A., Baccarani, M., Stone, R., Tura, S., Mahon, M.X., Fernandes-Reese, S., Gathmann, I., Capdeville, R., Kantarjian, H.M. and Sawyers, C.L. (2002) "Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study", Blood 99, 1928-1937.
25. Marley, S.B., Deininger, M.W.N., Davidson, R.J., Goldman, J.M. and Gordon, M.Y. (2000) "The tyrosine kinase inhibitor STI571, like interferon alpha preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia", Exp. Hematol. 28, 551-557.
26. Graham, S.M., Jorgensen, H.G., Allan, E., Pearson, C., Alcorn, M.J., Richmond, L. and Holyoake, T. (2002) "Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are intensive to STI571 in vitro", Blood 99, 319-325.
27. Holtz, M.S., Slovak, M.L., Zhang, F., Sawyers, C.L., Forman, S.J. and Bhatia, R. (2002) "Imanitib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation", Blood 99, 3792-3800.
28. Goldman, J.M. and Melo, J.V. (2001) "Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia", N. Engl. J. Med. 344, 1084-1086.
29. Chou, T.B. and Talalay, P. (1984) "Quantitative analysis of dose-effect relationships: the combined effect of multiple drugs or enzyme inhibitors", Adv. Enzyme Regul. 22, 27-55.
30. Fruehauf, S., Topaly, J., Laufs, S., Zeller, W.J. and Ho, A.D. (2001) "STI571-based combination therapy of chronic myelogenous leukemia: preclinical data", Blood 98, 257b.
31. Kano, Y., Akutsu, M., Tsunoda, S., Mano, H., Sato, Y., Honma, Y. and Furukawa, Y. (2001) "In vitro cytotoxic effect of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents", Blood 97, 1999-2007.
32. Marley, S.B., Davidson, J., Goldman, J.M. and Gordon, M.Y. (2002) "Effect of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia", Br. J. Haematol. 116, 162-165.
33. Topaly, J., Zeller, W.J. and Fruehauf, S. (2001) "Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells", Leukemia 15, 342-347.
34. Topaly, J., Zeller, W.J. and Fruehauf, S. (2002) "Combination therapy with Imatinib mesylate (STI571):synopsis of in vitro studies", Br. J. Haematol. 119, 3-14.
35. Scappini, B., Onida, F., Kantarjian, H.M., Dong, L., Verstovsek, S., Keating, M.J. and Beran, M. (2002) "In vitro effect of STI571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells", Cancer 94, 2653-2662.
36. Robak, T. (2003) "Purine nucleoside analogues in the treatment of myeloid leukemias", Leuk. Lymphoma 44, 391-409.